Related Experiment Video
Updated: Jul 8, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms]
K Kollewe1, R Dengler, S Petri
1Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, Hannover, Germany. Kollewe.Katja@mh-hannover.de
Abstract:
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to death after 3 to 5 years. The glutamate antagonist Riluzole currently is the only drug with marginal therapeutic benefit, but its effect on survival is modest, with an average increase of only 3-4 months. Therefore symptomatic treatment still is the most important. Further neuroprotective agents are currently under investigation, both in transgenic animal models of ALS and clinical trials in ALS patients. This review summarizes the current state of clinical studies in ALS patients in the context of underlying therapeutic mechanisms.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alzheimer Disease ll: Pathophysiology
Alterations in Muscle Tone lll

